Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer

Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses standard treatment for patients with metastatic urothelial cancer in the frontline setting and beyond.

Related Content:

Bladder Cancer
Adjuvant nivolumab data published in NEJM show DFS benefit in bladder cancer
Pembrolizumab demonstrates efficacy as part of trimodal treatment in bladder cancer
Adding eganelisib to nivolumab shows survival benefit in bladder cancer